|
| Figure 4: Depicts novel object recognition performance of mice (n = 12 / group) administered intracerebroventricular (i.c.v.), or intra-peritoneal (i.p.), saline or the peripherally-limited, kappa opioid receptor agonist, ffir-NH2 (3 nmol, i.c.v. or 1 mg / kg, i.p.), with or without nor-binaltorphimine (nor-BNI; 5 mg / kg, i.p.) pretreatment. *indicates significant interaction wherein mice in all groups spent a greater percentage of time with the novel object in Phase III except for saline-infused mice receiving ffir-NH2 (3 nmol, i.c.v.). |
